Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


VUMC Researchers Developing Potential Coronavirus Antibody Therapies


 
Dr. James Crowe Photo by: John Russell.

Vanderbilt University Medical Center (VUMC) is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Researchers from the Vanderbilt Vaccine Center (VVC) have rapidly responded to this outbreak by building a comprehensive "toolkit" to identify and analyze antibodies isolated from the blood of survivors for their ability to neutralize SARS-CoV-2, the virus that causes COVID-19.

Thousands of antibodies that already have been identified by VVC are now being analyzed for their ability to inhibit the virus and, more importantly, to prevent it from causing illness. The goal is to develop and manufacture the most promising lead antibodies in preparation for initiating clinical trials to test their efficacy in humans.

"Our goal is to prepare antibodies for human clinical trials by this summer," said James Crowe, MD, director of the Vanderbilt Vaccine Center.

"We have ultra-rapid antibody discovery technologies and already have discovered SARS-CoV-2 antibodies," Crowe said. "Our partners have the manufacturing and product development expertise to turn these antibodies into effective biological drugs very quickly."

VVC researchers have developed techniques for rapidly isolating clones of antibody-producing white blood cells, called "B" cells, which produce antibodies targeting specific viral proteins. In the laboratory, these "monoclonal" antibodies are then comprehensively examined to identify those rare antibodies with a laser-like focus for finding -- and neutralizing -- a specific virus.

Resources at VUMC that enable the researchers to map antibody sequences and antibody specificities simultaneously and in a high throughput way include the Medical Center's core genomics laboratory, Vanderbilt Technologies for Advanced Genomics (VANTAGE).

Using these techniques, they have generated human monoclonal antibodies against a wide range of pathogenic viruses including Ebola, chikungunya, HIV, dengue, norovirus and respiratory syncytial virus (RSV). They have pioneered the rational design of neutralizing antibody treatments and vaccines, some of which have progressed to clinical trials.

Major funding sources for the VVC include DARPA, the Defense Advanced Research Projects Agency of the U.S. Department of Defense (DoD) and the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.

The VVC is participating in DARPA's Pandemic Protection Platform (P3) program, a five-year cooperative agreement to develop protective antibody treatments that can be rushed to health care providers within 60 days after the outbreak of viral diseases anywhere in the world. "Our work over the past several years, through the DARPA Pandemic Prevention Platform (P3), has allowed us to define a flexible and rapid approach algorithm to pursue protective antibodies to almost any viral pathogen," said Robert Carnahan, PhD, VVC associate director.

Last year Carnahan and Crowe led a multi-institutional DARPA "sprint" that developed, in just 11 weeks, a protective antibody-based treatment aimed at stopping the spread of Zika, a mosquito-transmitted virus which can cause severe birth defects in babies whose mothers were infected when they were pregnant.

Vanderbilt's many academic partners in the effort to identify and validate anti-SARS-CoV2 human antibodies include the University of Washington School of Medicine in Seattle, Washington University School of Medicine in St. Louis, Emory University School of Medicine in Atlanta, University of North Carolina School of Medicine at Chapel Hill and Beth Israel Deaconess Medical Center in Boston. Additionally, a number of corporate partners are also bolstering Vanderbilt's research efforts.

Others in the VVC who are crucial to the research effort include Pavlo Gilchuk, PhD, senior staff scientist, Seth Zost, PhD, research fellow, Naveen Suryadevara, PhD, staff scientist, Nurgun Kose, senior research specialist, research assistants Rachel Sutton and Erica Armstrong, lab managers Rachel Nargi and Ryan Irving, and project managers Merissa Mayo and Ginger DeBellis.

WEB:

Vanderbilt Vaccine Center

 
Share:

Related Articles:


Recent Articles

Study Challenges Idea That Lower BMI Shields Smokers from Fat-associated Health Risk

A lower body mass index (BMI) does not protect smokers from fat-associated health risks, according to a Vanderbilt University Medical Center (VUMC) study published in PLOS Medicine.

Read More

Nearly One-Third of Tennessee Parents are Worried Their Child has an Undiagnosed Mental Health Condition, New Poll Finds

One-third of Tennessee parents with children ages 6-17 are worried their child has an undiagnosed mental health condition, a new poll from the Vanderbilt Center for Child Health Policy found.

Read More

COVID-19 - Where We Stand

As the city moves deeper into reopening, leaders address the need for ongoing precautions and realities of vaccine development.

Read More

AMA Issues New Privacy Principles

From a fitness tracker to healthy eating app, data is everywhere ... but it isn't all protected by HIPAA. The AMA has created a set of privacy principles that put patients in charge of their information.

Read More

Paycheck Protection Program Flexibility Act

Deadlines and information on PPP and provider relief fund.

Read More

"What's Up Doc?" Dealing with a Delayed Patient Volume Bounce

Read More

Financing the Deal

The Nashville Health Care Council's annual "Financing the Deal" panel discussion is always highly anticipated. This year's virtual event was as popular as ever with a focus on deal-making trends and strategies.

Read More

Lending a Hand

Mentorship, wisdom offered to start-ups through Nashville Entrepreneur Center.

Read More

Health Care Council Explores the Road to Economic Recovery

Read More

Nashville-Based Startups Launch New Charity Initiatives

Charity-tech brands GeekCause, Generous, Givful and Kindful have jointly announced a range of new initiatives to support the important work of nonprofits during the COVID-19 pandemic.

Read More

Email Print
 
 

 

 


Tags:
Coronavirus Antibodies, Coronavirus Treatment, James Crowe, Robert Carnahan, Vanderbilt University Medical Center, Vanderbilt Vaccine Center, VUMC, VVC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: